2023 Was a tricky yr with the biopharma business, with numerous organizations downsizing and restructuring their workforces to remain afloat. There are signs of recovery, as mergers and acquisitions picked up through the pharmaceutical and existence sciences industry while in the latter part of 2023 and also have continued their https://sites.google.com/view/bio-sites/blog